(R)-2-(3-{2-[2-(4-benzyloxy-3-methanesulfonamidophenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]acetamide hemifumarate | 862541-45-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-(3-{2-[2-(4-benzyloxy-3-methanesulfonamidophenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]acetamide hemifumarate
• 英文别名: N-[(4’-hydroxybiphenyl-3-yl)methyl]-2-(3-{2-[((2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-2-methylpropyl}phenyl)acetamide；N-[(4'-hydroxybiphenyl-3-yl)methyl]-2-[3-(2-{[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide；PF-00610355；PF-610355；N-[(4'-hydroxybiphenyl-3-yl)methyl]-2-(3-{2-[((2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-2-methylpropyl}phenyl)acetamide；Benzeneacetamide, N-((4'-hydroxy(1,1'-biphenyl)-3-yl)methyl)-3-(2-(((2R)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)-；2-[3-[2-[[(2R)-2-hydroxy-2-[4-hydroxy-3-(methanesulfonamido)phenyl]ethyl]amino]-2-methylpropyl]phenyl]-N-[[3-(4-hydroxyphenyl)phenyl]methyl]acetamide
• CAS: 862541-45-5
• 化学式: C₃₄H₃₉N₃O₆S
• 分子量: 617.766
• InChiKey: YPHDIMUXXABSSO-YTTGMZPUSA-N

物化性质

• 熔点：
  198 °C
• 密度：
  1.301±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  44
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  156
• 氢给体数：
  6
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N-(5-乙酰基-2-(苄氧基)苯基)甲磺酰胺 在 咪唑 、 氟化铵 、 硼酸三甲酯 、 dimethyl sulfide borane 、 20% palladium hydroxide on charcoal 、 甲酸铵 、 tetra-N-butylammonium tribromide 、 (R)-(+)-alpha,alpha-二苯基脯氨醇 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 146.75h， 生成 (R)-2-(3-{2-[2-(4-benzyloxy-3-methanesulfonamidophenyl)-2-hydroxyethylamino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]acetamide hemifumarate
  参考文献：
  名称：

  Development of an Enabling Route to PF-00610355: A Novel Inhaled β₂-Adrenoreceptor Agonist

  摘要：

  The initial route used to prepare PF-00610355 (8) for early clinical development is described. Through careful choice of solvent, an efficient, telescoped route to carboxylic acid 23 was developed, affording this late-stage intermediate in 80% yield over 4 steps. Deprotection of 23 to give sodium salt 24a and coupling with amine 6 center dot HCl afforded the desired API. Effective synthetic routes to two of the starting materials, chiral bromide 1 and amine 6, are also described.

  DOI：

  10.1021/op2001904

文献信息

• Inhibitors of nedd8-activating enzyme
  申请人：IP Gesellschaft für Management mbH

  公开号：EP2764866A1

  公开（公告）日：2014-08-13

  The invention relates to an administration unit comprising crystalline form I of (1 S,2S,4R)-4-[(6-[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

  该发明涉及一种包含晶型I的(1S,2S,4R)-4-[(6-[(1R,2S)-5-氯-2甲氧基-2,3-二氢-1H-茚-1-基]氨基}嘧啶-4-基)氧基]-2-羟基环戊基}甲基磺酰胺(I-216)盐酸盐的管理单元，以及包括该管理单元的包装。
• Sulfonamide derivatives for the treatment of diseases
  申请人：Brown Daniel Alan

  公开号：US20050182091A1

  公开（公告）日：2005-08-18

  The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  该发明涉及公式（1）的化合物，以及用于制备、用于制备的中间体、含有和使用这些衍生物的组合物的过程。根据本发明的化合物在许多疾病、紊乱和状况中具有用途，特别是在炎症性、过敏性和呼吸系统疾病、紊乱和状况中。
• [EN] INTERMEDIATE AND PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE<br/>[FR] INTERMÉDIAIRE ET PROCÉDÉ DE PRÉPARATION D'UN DÉRIVÉ SULFONAMIDE
  申请人：PFIZER LTD

  公开号：WO2013021309A1

  公开（公告）日：2013-02-14

  The invention relates to a crystalline form of 2-chloro-N-2-[3-(2-[(4'-hydroxybiphenyl-3- yl)methyl]amino}-2-oxoethyl)phenyl]-1,1-dimethylethyl}acetamide, a process for preparing the same and its use in the preparation of the 2 agonist N-[(4'-hydroxybiphenyl-3- yl)methyl]-2-(3-2-[((2R)-2-hydroxy-2-4-hydroxy-3- [(methylsulfonyl)amino]phenyl}ethyl)amino]-2-methylpropyl} phenyl)acetamide which is useful in the treatment of respiratory diseases.

  该发明涉及一种结晶形式的2-氯-N-2-[3-(2-[(4'-羟基联苯-3-基)甲基]氨基}-2-氧乙基)苯基]-1,1-二甲基乙基}乙酰胺，以及其制备方法和在制备β2激动剂N-[(4'-羟基联苯-3-基)甲基]-2-(3-2-[((2R)-2-羟基-2-4-羟基-3-[(甲磺酰)氨基]苯基}乙基)氨基]-2-甲基丙基}苯基)乙酰胺中的应用，该激动剂在呼吸系统疾病治疗中有用。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2015140527A1

  公开（公告）日：2015-09-24

  The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).

  本发明提供了一种化合物，其化学式为（I）或其药用可接受的盐；一种制备这种化合物的方法；以及利用这种化合物治疗ENaC介导的疾病状态（如哮喘、囊性纤维化或慢性阻塞性肺病）的用途。
• Process for the Preparation of Sulfonamide Derivatives
  申请人：Gladwell Iain Robert

  公开号：US20080193988A1

  公开（公告）日：2008-08-14

  The invention relates to a process for the preparation of compounds of formula (I) wherein Q 1 is a group selected from formulae (II) & (III) and a group *-NR 6 -Q 2 -A or, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof, as well as intermediates used in said process.

  本发明涉及一种制备式（I）化合物的过程，其中Q1是从式（II）和（III）中选择的基团以及基团*-NR6-Q2-A，或者在适当的情况下，它们的药学上可接受的盐和/或异构体、互变异构体、溶剂化物或同位素变体，以及用于该过程的中间体。